

SUBSTITUTE FOR FORM IPC/SB/08  INFORMATION DISCLOSURE STATEMENT LIST OF DOCUMENTS CITED BY APPLICANT		ATTY DOCKET NO: KOGANTY=4A	SERIAL NO: 10/511,101			
		FIRST INVENTOR: KOGANTY, R.				
		FILING DATE: September 12, 2005				
		EXAMINER:	ART UNIT: 1643			
U.S. PATENT DOCUMENTS (include at least patentee, patent/pub number and issue date)						
EXAM. INITIAL	ID	DOCUMENT NUMBER	FILING, ISSUE OR PUBLICATION DATE MM-DD-YYYY	PATENTEE OR APPLICANT	Relevant Passage(s)	T*
AK	4,235,871		11-25-1980	PAPAHADJOPOULOS, et al.		
AB	4,501,728		02-26-1985	GEHO et al.		
AC	4,837,028		06-06-1989	ALLEN		
AD	4,868,155		09-19-1989	DURETTE, et al.		
AE	5,019,369		05-28-1991	PRESANT, et al.		
AF	5,019,383		05-28-1991	HOPP		
AG	5,744,144		04-28-1998	FINN, et al.		
AH	5,837,249		11-17-1998	HEBER-KATZ, et al.		
AI	5,871,746		02-16-1999	BOUTILLON, et al.		
AJ	5,993,823		11-30-1999	BOUTILLON, et al.		
AK	6,013,779		01-11-2000	WONG, et al.		
AL	6,015,564		01-18-2000	BOUTILLON, et al.		
AM	6,344,203		02-05-2002	SANDRIN, et al.		
FOREIGN PATENT DOCUMENTS (include at least document number, publication date and country)						
EXAM. INITIAL	ID	COUNTRY CODE & DOCUMENT NUMBER	PUBLICATION DATE MM-DD-YYYY	PATENTEE OR APPLICANT	Relevant Passage(s)	T*
AN	WO 93/21211		10-28-1993	LABORATORIOS MENARINI		E
AQ	WO 95/27505		10-19-1995	BIOMIRA, INC.		E
AP	WO 01/36433		05-25-2001	BIOMIRA, INC.		E
AQ	WO 02/076485		10-03-2002	BUDZYNSKI		E
AR	EP 0 093 851		11-16-1983	NEW YORK BLOOD CENTER, INC		E
AS	EP 0 203 676		12-03-1986	THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY		E
AT	EP 0 230 893		08-05-1987	BRACCO INDUSTRIA CHIMICA		E
EXAMINER			DATE CONSIDERED			
EXAMINER: Initial if reference considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						

\* "Relevant Passages" column is optional. Put check in "T" column if English translation of entire document included. If English language abstract included, put A in this box. If ref. in English, put "E". If requirement otherwise met, put O.

SUBSTITUTE FOR FORM IPC/SB/08		ATTY DOCKET NO: KOGANTY=4A		SERIAL NO: 10/511,101		
INFORMATION DISCLOSURE STATEMENT LIST OF DOCUMENTS CITED BY APPLICANT		FIRST INVENTOR: KOGANTY, R.				
		FILING DATE: September 12, 2005				
		EXAMINER:		ART UNIT: 1643		
FOREIGN PATENT DOCUMENTS (include at least document number, publication date and country)						
EXAM. INITIAL	ID	COUNTRY CODE & DOCUMENT NUMBER	PUBLICATION DATE MM-DD-YYYY	PATENTEE OR APPLICANT	Relevant Passage(s)	T*
	AU	EP 0 491 628	06-24-1992	PASTEUR INSTITUTE, et al.		A
	AV	EP 0 945 461	09-29-1999	PASTEUR INSTITUTE, et al.		A
	AW	EP 1 065 212	01-03-2001	PASTEUR INSTITUTE, et al.		A
	AX	EP 1 182 210	02-27-2002	BASTERT, Gunter, et al.		E
OTHER DOCUMENTS (include AUTHOR, title, name of publication, volume, pages & date of publication) Please list in alphabetical order.						
	AY	BROSSART, et al., "Identification of HLA-A2-Restricted T-Cell Epitopes Derived From the MUC1 Tumor Antigen for Broadly Applicable Vaccine Therapies", <u>BLOOD</u> , vol. 93, no. 12, pp. 4309-4317, June 15, 1999.				
	AZ	CARMON, et al., "Novel Breast-Tumor-Associated MUC1-Derived Peptides: Characterization in D <sup>b</sup> /- X β2 Microglobulin (β2m) Null Mice Transgenic for a Chimeric HLA-A2.1/D <sup>b</sup> -β2 Microglobulin Single Chain", <u>INT. J. CANCER</u> , vol. 85, pp. 391-397, 2000.				
	BA	DENTON, et al., "Sequential Order of T and B Cell Epitopes Affects Immunogenicity But Not Antibody Recognition of the B Cell Epitope", <u>PEPTIDE RESEARCH</u> , vol. 7, no. 5, pp. 258-264, 1994.				
	BB	DIEZ-BARRA, et al., Chemical Abstract, "Solvent-free phase transfer catalysis. Improvements on serine O-alkylation, Database accession no. 127:220955, 1997.				
	BC	ENGELMANN, et al., "Identification and Topology of Variant Sequences within Individual Repeat Domains of the Human Epithelial Tumor Mucin MUC1", <u>THE JOURNAL OF BIOLOGICAL CHEMISTRY</u> , vol. 276, no. 30, pp. 27764-27769, July 27, 2001.				
	BD	GENDLER, et al., "A Highly Immunogenic Region of a Human Polymorphic Epithelial Mucin Expressed by Carcinomas Is Made Up of Tandem Repeats", <u>THE JOURNAL OF BIOLOGICAL CHEMISTRY</u> , vol. 263, no. 26, pp. 12820-12823, September 15, 1988.				
	BE	HEUKAMP, et al., "Identification of Three Non-VNTR MUC1-Derived HLA-A*0201-Restricted T-Cell Epitopes that Induce Protective Anti-Tumor Immunity in HLA-A2/K <sup>b</sup> -Transgenic Mice", <u>INT. J. CANCER</u> , vol. 91, pp. 385-392, 2001.				
	BF	HILTBOLD, et al., "Naturally Processed Class II Epitope from the Tumor Antigen MUC1 Primes Human CD4 <sup>+</sup> T Cells", <u>CANCER RESEARCH</u> , vol. 58, pp. 5066-5070, November 15, 1998.				
	BG	KEIL, et al., "Towards the Development of Antitumor Vaccines: A Synthetic Conjugate of a Tumor-Associated MUC1 Glycopeptide Antigen and a Tetanus Toxin Epitope", <u>ANGEW. CHEM. INT. ED.</u> , vol. 40, no. 2, pp. 366-369, 2001.				
EXAMINER			DATE CONSIDERED			
EXAMINER: Initial if reference considered. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant.						

\* "Relevant Passages" column is optional. Put check in "T" column if English translation of entire document included. If English language abstract included, put A in this box. If ref. in English, put "E". If requirement otherwise met, put O.

SUBSTITUTE FOR FORM IPC/SB/08 U. S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO: KOGANTY=4A	SERIAL NO: 10/511,101
INFORMATION DISCLOSURE STATEMENT LIST OF DOCUMENTS CITED BY APPLICANT		FIRST INVENTOR: KOGANTY, R.	
		FILING DATE: September 12, 2005	
		EXAMINER:	ART UNIT: 1643
OTHER DOCUMENTS (include author, title, name of publication, volume, pages and date of publication)			
	BH	KUDRYASHOV, et al., "Toward optimized carbohydrate-based anticancer vaccines: Epitope clustering, carrier structure, and adjuvant all influence antibody responses to Lewis' conjugates in mice", <u>PNAS</u> , vol. 98, no. 6, pp. 3264-3269, March 13, 2001.	
	BI	MARTINON, et al., "Immunization of Mice with Lipopeptides Bypasses the Prerequisite for Adjuvant", <u>THE JOURNAL OF IMMUNOLOGY</u> , vol. 149, no. 10, pp. 3416-3422, November 15, 1992.	
	BJ	MEYLAN, et al., "Atom/Fragment Contribution Method for Estimating Octanol-Water Partition Coefficients", <u>JOURNAL OF PHARMACEUTICAL SCIENCES</u> , vol. 84, no. 1, pp. 83-92, January 1995.	
	BK	MÖLLER, et al., "NMR-based determination of the binding epitope and conformational analysis of MUC-1 glycopeptides and peptides bound to the breast cancer-selective monoclonal antibody SM3", <u>EUR. J. BIOCHEM.</u> , vol. 269, pp. 144-1455, 2002.	
	BL	MORTARA, et al., "Selection of Virus Variants and Emergence of Virus Escape Mutants after Immunization with an Epitope Vaccine", <u>JOURNAL OF VIROLOGY</u> , vol. 72, no. 2, pp. 1403-1410, February 1998.	
	BM	PETRAKOU, et al., "Epitope Mapping of Anti-MUC1 Mucin Protein Core Monoclonal Antibodies", <u>TUMOR BIOL.</u> , vol. 19(suppl 1), pp. 21-29, 1998.	
	BN	REICHEL, et al., "Synthetic carbohydrate-based vaccines: synthesis of an L-glycero-D-manno-heptose antigen-T-epitope-lipopeptide conjugate", <u>CHEM. COMMUN.</u> , pp. 2087-2088, 1997.	
	BO	SAUZET, et al., "Long-lasting anti-viral cytotoxic T lymphocytes induced in vivo with chimeric-multirestricted lipopeptides", <u>VACCINE</u> , vol. 13, no. 14, pp. 1339-1345, 1995.	
	BP	SOARES, et al., "Three Different Vaccines Based on the 140-Amino Acid MUC1 Peptide with Seven Tandemly Repeated Tumor-Specific Epitopes Elicit Distinct Immune Effector Mechanisms in Wild-Type Versus MUC1-Transgenic Mice with Different Potential for Tumor Rejection", <u>THE JOURNAL OF IMMUNOLOGY</u> , vol. 166, pp. 6555-6563, 2001.	
	BQ	SPRINGER, Georg F., "T and Tn, General Carcinoma Autoantigens", <u>SCIENCE</u> , vol. 224, pp. 1198-1206, June 15, 1984.	
	BR	TAYLOR-PAPADIMITRIOU, et al., "Molecular aspects of mucins", <u>CANCER REV.</u> , vol. 11-12, pp. 11-24, 1988.	
	BS	TOYOKUNI, et al., "Synthetic Vaccines: Synthesis of a Dimeric Tn Antigen-Lipopeptide Conjugate That Elicits Immune Responses against Tn-Expressing Glycoproteins", <u>J. AM. CHEM. SOC.</u> , vol. 116, pp. 395-396, 1994.	
EXAMINER		DATE CONSIDERED	
EXAMINER: Initial if reference considered. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant.			

<p>SUBSTITUTE FOR FORM IPC/SB/08 U. S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE</p> <p>INFORMATION DISCLOSURE STATEMENT LIST OF DOCUMENTS CITED BY APPLICANT</p>		ATTY DOCKET NO: KOGANTY=4A	SERIAL NO: 10/511,101																																														
		FIRST INVENTOR: KOGANTY, R.																																															
		FILING DATE: September 12, 2005																																															
		EXAMINER:	ART UNIT: 1643																																														
<p>OTHER DOCUMENTS (include author, title, name of publication, volume, pages and date of publication)</p> <table border="1"> <tr> <td>BT</td> <td>VITIELLO, et al., "Development of a Lipopeptide-based Therapeutic Vaccine to Treat Chronic HBV Infection", <u>J. CLIN. INVEST.</u>, vol. 95, pp. 341-349, January 1995.</td> </tr> <tr> <td>BU</td> <td>VON MENSDORFF-POUILLY, et al., ABSTRACT ONLY, "Human MUC1 mucin: a multifaceted glycoprotein", <u>INT. J. BIOL. MARKERS</u>, vol. 15(4), pp. 343-56, October-December 2000.</td> </tr> <tr> <td>BV</td> <td>VON MENSDORFF-POUILLY, et al., "Reactivity of Natural and Induced Human Antibodies to MUC1 Mucin with MUC1 Peptides and N-Acetylgalactosamine (GalNAc) Peptides", <u>INT. J. CANCER</u>, vol. 86, pp. 702-712, 2000.</td> </tr> <tr> <td>BW</td> <td>VON MENSDORFF-POUILLY, et al., "Survival in Early Breast Cancer Patients Is Favorably Influenced by a Natural Humoral Immune Response to Polymorphic Epithelial Mucin", <u>JOURNAL OF CLINICAL ONCOLOGY</u>, vol. 18, no. 3, pp. 574-583, February 2000.</td> </tr> <tr><td></td><td></td></tr> <tr> <td>EXAMINER</td> <td colspan="2">DATE CONSIDERED</td> </tr> <tr> <td colspan="3"> <p>EXAMINER: Initial if reference considered. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant.</p> </td> </tr> </table>				BT	VITIELLO, et al., "Development of a Lipopeptide-based Therapeutic Vaccine to Treat Chronic HBV Infection", <u>J. CLIN. INVEST.</u> , vol. 95, pp. 341-349, January 1995.	BU	VON MENSDORFF-POUILLY, et al., ABSTRACT ONLY, "Human MUC1 mucin: a multifaceted glycoprotein", <u>INT. J. BIOL. MARKERS</u> , vol. 15(4), pp. 343-56, October-December 2000.	BV	VON MENSDORFF-POUILLY, et al., "Reactivity of Natural and Induced Human Antibodies to MUC1 Mucin with MUC1 Peptides and N-Acetylgalactosamine (GalNAc) Peptides", <u>INT. J. CANCER</u> , vol. 86, pp. 702-712, 2000.	BW	VON MENSDORFF-POUILLY, et al., "Survival in Early Breast Cancer Patients Is Favorably Influenced by a Natural Humoral Immune Response to Polymorphic Epithelial Mucin", <u>JOURNAL OF CLINICAL ONCOLOGY</u> , vol. 18, no. 3, pp. 574-583, February 2000.																																	EXAMINER	DATE CONSIDERED		<p>EXAMINER: Initial if reference considered. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant.</p>		
BT	VITIELLO, et al., "Development of a Lipopeptide-based Therapeutic Vaccine to Treat Chronic HBV Infection", <u>J. CLIN. INVEST.</u> , vol. 95, pp. 341-349, January 1995.																																																
BU	VON MENSDORFF-POUILLY, et al., ABSTRACT ONLY, "Human MUC1 mucin: a multifaceted glycoprotein", <u>INT. J. BIOL. MARKERS</u> , vol. 15(4), pp. 343-56, October-December 2000.																																																
BV	VON MENSDORFF-POUILLY, et al., "Reactivity of Natural and Induced Human Antibodies to MUC1 Mucin with MUC1 Peptides and N-Acetylgalactosamine (GalNAc) Peptides", <u>INT. J. CANCER</u> , vol. 86, pp. 702-712, 2000.																																																
BW	VON MENSDORFF-POUILLY, et al., "Survival in Early Breast Cancer Patients Is Favorably Influenced by a Natural Humoral Immune Response to Polymorphic Epithelial Mucin", <u>JOURNAL OF CLINICAL ONCOLOGY</u> , vol. 18, no. 3, pp. 574-583, February 2000.																																																
EXAMINER	DATE CONSIDERED																																																
<p>EXAMINER: Initial if reference considered. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant.</p>																																																	